- Home
- ANTX vs NRXP Comparison
ANTX vs NRXP Comparison
Compare ANTX & NRXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANTX | NRXP |
|---|---|---|
| Founded | 2017 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.1M | 63.5M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANTX | NRXP |
|---|---|---|
| Price | $1.19 | $2.07 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | $2.00 | ★ $30.50 |
| AVG Volume (30 Days) | 54.8K | ★ 452.8K |
| Earning Date | 11-12-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $242,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $643.59 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.01 | $1.17 |
| 52 Week High | $1.55 | $6.01 |
Technical Indicators
Market Signals| Indicator | ANTX | NRXP |
|---|---|---|
| Relative Strength Index (RSI) | 61.12 | 37.62 |
| Support Level | $1.12 | $2.22 |
| Resistance Level | $1.21 | $2.39 |
| Average True Range (ATR) | 0.07 | 0.15 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 86.36 | 4.26 |
Price Performance
Historical ComparisonAbout ANTX AN2 Therapeutics Inc.
AN2 Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics derived from its boron chemistry platform. The company has a pipeline of boron-based compounds in development for Chagas disease, non-tuberculous mycobacterial (NTM) and melioidosis, along with early-stage programs focused on targets in infectious diseases and oncology.
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.